ArticleCureus2023
Role of Ceramide Synthase 1 in Oral Leukoplakia and Oral Squamous Cell Carcinoma: A Potential Linchpin for Tumorigenesis.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Ceramide (CER), known as a "tumor suppressor lipid," plays a crucial role in promoting apoptosis in cancer cells. Ceramide synthase 1 (CERS1), an enzyme responsible for CER synthesis, holds immense importance. Notably, studies have highlighted that reduced levels of CERS1 confer protection to oral squamous cell carcinoma (OSCC) cells against chemotherapeutic agents like cisplatin. However, there is a scarcity of literature exploring the precise role of CERS1 in OSCC. Further investigation is warranted to unravel the intricate relationship of CERS1 in malignant transformation. Aim To compare the salivary CERS1 levels in OSCC, oral leukoplakia (OLK), and healthy individuals. Materials and methods Salivary samples from 15 healthy individuals, OLK patients, and OSCC patients each were obtained and an enzyme-linked immunosorbent assay (ELISA) (MyBioSource, Inc., San Diego, CA) was performed to evaluate salivary CERS1 enzyme levels. Descriptive statistics and Kruskal-Wallis analysis were done using SPSS v23.0 software (IBM Corp., Armonk, NY). Results There was a significant decrease in salivary CERS1 enzyme levels in OSCC (2.08 +/- 0.36 ng/dl) compared to healthy individuals (6.42 +/- 0.42 ng/dl) and OLK patients (4.73 +/- 0.93 ng/dl) (p = 0.05). Conclusion In this study, it was found that CERS1 shows a steady decrease in OLK and OSCC. Further cohort studies with larger sample sizes are needed to provide a basis for the role of CERS1 in OLK and its malignant transformation to OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.